<DOC>
	<DOCNO>NCT01009957</DOCNO>
	<brief_summary>The study evaluate whether administration everolimus ( 1.5 mg/day ) slow progression CKD ADPKD patient .</brief_summary>
	<brief_title>Everolimus CKD Progression ADPKD Patients</brief_title>
	<detailed_description>Considering inhibitor activity Everolimus mTOR , hypothesis evaluate possible utility progression CKD ADPKD patient reduce rate increase renal cyst .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subjects 18 year gender 2 . Clinical diagnosis autosomal dominant polycystic kidney disease ( ADPKD ) 3 . GFR , accord MDRD formula , 30 90 ml/min/1.73 mq 4 . Previous follow two year , creatinine evaluation least year 5 . GFR reduction least 2.5 ml/min/year ( accord MDRD formula ) 1 . Pregnancy , lactating , male female without adequate contraception 2 . Leucopenia ( &lt; 3,000 leucocytes/mm3 ) thrombocytopenia ( &lt; 100,000 platelets/mm3 ) 3 . Dyslipidemia ( cholesterol triglycerides &gt; 260 mg/dl treatment ) 4 . Urinary tract infection 5 . Patients undergo NMR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>CKD</keyword>
	<keyword>Renal disease progression</keyword>
	<keyword>Everolimus</keyword>
</DOC>